This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halmos, G. Articles by Rekasi, Z. Search for Related Content PubMed PubMed Citation Articles by Halmos, G. Articles by Rekasi, Z.

Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer

Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, and Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112

Address all correspondence and requests for reprints to: Dr. Andrew V. Schally, Veterans Affairs Medical Center, 1601 Perdido Street, New Orleans, Louisiana 70112-1262.

Abstract

Antagonists of GHRH inhibit the growth of various human tumors, including prostate cancer, but the tumoral receptors mediating the antiproliferative effect of GHRH antagonists have not been clearly identified. Recently, we demonstrated that human cancer cell lines express splice variants (SVs) of receptors for GHRH, of which SV1 exhibits the greatest similarity to the pituitary GHRH receptors. In this study we investigated the expression of GHRH and SVs of GHRH receptor and the binding characteristics of the GHRH receptor isoform in 20 surgical specimens of organ-confined and locally advanced human prostatic adenocarcinomas. The mRNA expression of GHRH and SVs of GHRH receptor was investigated by RT-PCR. The affinity and density of receptors for GHRH were determined by ligand competition assays based on binding of ¹²⁵I-labeled GHRH antagonist JV-1-42 to tumor membranes. Twelve of 20 tumors (60%) exhibited specific, high affinity binding for JV-1-42, with a mean dissociation constant (K_d) of 0.81 nmol/liter and a mean maximal binding capacity of 185.2 fmol/mg membrane protein. The mRNA of SV1 was detected in 13 of 20 (65%) prostate cancer specimens and was consistent with the presence of GHRH binding. RT-PCR analyses also revealed the expression of mRNA for GHRH in 13 of 15 (86%) prostatic carcinoma specimens examined. The presence of GHRH and its tumoral receptor SVs in prostate cancers suggests the possible existence of an autocrine mitogenic loop. The antitumor effects of GHRH antagonists in prostate cancer could be exerted in part by interference with this local GHRH system.

This article has been cited by other articles:

				S.-H. Tan and M. T Nevalainen Signal transducer and activator of transcription 5A/B in prostate and breast cancers Endocr. Relat. Cancer, June 1, 2008; 15(2): 367 - 390. [Abstract] [Full Text] [PDF]

				N. Barabutis, E. Tsellou, A. V. Schally, S. Kouloheri, A. Kalofoutis, and H. Kiaris Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor PNAS, March 27, 2007; 104(13): 5575 - 5579. [Abstract] [Full Text] [PDF]

				S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel PNAS, February 6, 2007; 104(6): 1943 - 1946. [Abstract] [Full Text] [PDF]

				F. Hohla, A. V. Schally, K. Szepeshazi, J. L. Varga, S. Buchholz, F. Koster, E. Heinrich, G. Halmos, F. G. Rick, C. Kannadka, et al. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel PNAS, September 26, 2006; 103(39): 14513 - 14518. [Abstract] [Full Text] [PDF]

				A. Havt, A. V. Schally, G. Halmos, J. L. Varga, G. L. Toller, J. E. Horvath, K. Szepeshazi, F. Koster, K. Kovitz, K. Groot, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues PNAS, November 29, 2005; 102(48): 17424 - 17429. [Abstract] [Full Text] [PDF]

				L. B. Jaeger, W. A. Banks, J. L. Varga, and A. V. Schally Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: A potential applicability to treatment of brain tumors PNAS, August 30, 2005; 102(35): 12495 - 12500. [Abstract] [Full Text] [PDF]

				G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone PNAS, July 26, 2005; 102(30): 10628 - 10633. [Abstract] [Full Text] [PDF]

				J. B. Engel, G. Keller, A. V. Schally, G. L. Toller, K. Groot, A. Havt, P. Armatis, M. Zarandi, J. L. Varga, and G. Halmos Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3614 - 3621. [Abstract] [Full Text] [PDF]

				Z. Rekasi, T. Czompoly, A. V. Schally, F. Boldizsar, J. L. Varga, M. Zarandi, T. Berki, R. A. Horvath, and P. Nemeth Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway PNAS, March 1, 2005; 102(9): 3435 - 3440. [Abstract] [Full Text] [PDF]

				A. Stangelberger, A. V. Schally, J. L. Varga, M. Zarandi, K. Szepeshazi, P. Armatis, and G. Halmos Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice Clin. Cancer Res., January 1, 2005; 11(1): 49 - 57. [Abstract] [Full Text] [PDF]

				G. L. Toller, J. E. Horvath, A. V. Schally, G. Halmos, J. L. Varga, K. Groot, D. Chism, and M. Zarandi Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors PNAS, October 19, 2004; 101(42): 15160 - 15165. [Abstract] [Full Text] [PDF]

				Z. Szereday, A. V. Schally, J. L. Varga, C. A. Kanashiro, F. Hebert, P. Armatis, K. Groot, K. Szepeshazi, G. Halmos, and R. Busto Antagonists of Growth Hormone-Releasing Hormone Inhibit the Proliferation of Experimental Non-Small Cell Lung Carcinoma Cancer Res., November 15, 2003; 63(22): 7913 - 7919. [Abstract] [Full Text] [PDF]

				H. Kiaris, I. Chatzistamou, A. V. Schally, G. Halmos, J. L. Varga, H. Koutselini, and A. Kalofoutis Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor PNAS, August 5, 2003; 100(16): 9512 - 9517. [Abstract] [Full Text] [PDF]

				K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker International Union of Pharmacology. XXXV. The Glucagon Receptor Family Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194. [Abstract] [Full Text] [PDF]

				M. Letsch, A. V. Schally, R. Busto, A. M. Bajo, and J. L. Varga Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers PNAS, February 4, 2003; 100(3): 1250 - 1255. [Abstract] [Full Text] [PDF]